Amedisys, Inc. (NASDAQ:AMED) is ClearAlpha Technologies LP's 8th Largest Position

ClearAlpha Technologies LP cut its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 23.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 59,653 shares of the health services provider's stock after selling 18,208 shares during the period. Amedisys comprises 3.7% of ClearAlpha Technologies LP's portfolio, making the stock its 8th largest holding. ClearAlpha Technologies LP owned approximately 0.18% of Amedisys worth $5,416,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Blue Trust Inc. increased its stake in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after buying an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new position in shares of Amedisys in the fourth quarter worth about $38,000. Versant Capital Management Inc grew its position in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after purchasing an additional 183 shares in the last quarter. Vestcor Inc bought a new stake in Amedisys during the 4th quarter valued at approximately $73,000. Finally, Venturi Wealth Management LLC lifted its holdings in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after purchasing an additional 779 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on AMED. Stephens reaffirmed an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $100.75.

Amedisys Trading Up 0.2 %

NASDAQ:AMED traded up $0.23 during midday trading on Friday, hitting $94.50. 361,426 shares of the company traded hands, compared to its average volume of 405,577. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The firm has a market capitalization of $3.10 billion, a P/E ratio of 37.50, a P/E/G ratio of 1.78 and a beta of 0.89. The firm's fifty day moving average is $92.21 and its 200-day moving average is $91.82.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating the consensus estimate of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. On average, sell-side analysts predict that Amedisys, Inc. will post 4.4 EPS for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.